pembrolizumab plus nabpaclitaxel

2 trials

Sponsors

Hoffmann La Roche

Conditions

Cancer

Phase 2

A Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Active, not recruitingPACTR202404480503746

Hoffmann La RocheCancer

Start: 2024-04-30Target: 160Updated: 2026-09-14

A Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer_

Active, not recruitingPACTR202405736542144

Hoffmann La RocheCancer

Start: 2024-06-03Target: 160Updated: 2026-09-14